Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Rhea-AI Summary

Alumis (Nasdaq: ALMS) will report topline results from the Phase 3 ONWARD program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026.

The company will host a conference call and webcast to discuss the topline data at 8:00 a.m. ET. Investors may access the live webcast via the company’s Investors > Events page at www.alumis.com. A replay of the webcast will be available on the company website after the call.

Key Figures

Trial phase Phase 3 ONWARD clinical program for envudeucitinib in plaque psoriasis

Conference time 8:00 a.m. ET Start time for Jan 6, 2026 conference call and webcast

Market Reality Check

$19.56 Last Close

Volume Volume 1,837,814 is 1.52x the 20-day average of 1,207,610, indicating elevated trading ahead of the data update. high

Technical Shares at $8.31 are trading above the 200-day MA of $5.27, despite a -8.25% move today and sitting 33.2% below the 52-week high.

Peers on Argus

ALMS fell 8.25% on higher volume, while peers like ATXS (-0.31%), ERAS (-2.24%), PRTA (-1.52%) and ITOS (+0.10%) saw more modest moves, pointing to a stock-specific reaction ahead of the Phase 3 ONWARD topline.

Common Catalyst Both ALMS and peer CRVS flagged upcoming clinical data and investor events, suggesting a period of data-centric catalysts in the biotech cohort.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 13	Earnings update	Neutral	+0.8%	Reported Q3 2025 results, cash runway into 2027, and key trial timelines.
Nov 04	Investor conferences	Neutral	-0.2%	Outlined participation in November 2025 healthcare investor conferences and webcasts.
Aug 29	Investor conferences	Neutral	-1.3%	Announced attendance at six major September 2025 healthcare conferences with webcasts.
Aug 13	Earnings update	Positive	-0.7%	Reported Q2 2025 results, ACELYRIN merger gain and strong cash position funding into 2027.
Jul 24	Clinical milestone	Positive	+0.5%	Completed enrollment in global LUMUS Phase 2b SLE trial with 408 patients over 48 weeks.

Pattern Detected

Recent news flow has produced relatively modest price moves, with one divergence where seemingly positive earnings and merger-related updates coincided with a slight decline.

Recent Company History

Over the past six months, Alumis has focused on advancing late-stage immune-mediated disease programs and building its balance sheet. The company completed enrollment in the global LUMUS Phase 2b SLE trial and highlighted that Phase 3 ONWARD psoriasis topline data were expected in early Q1 2026, aligning with today’s announcement of the upcoming data release and webcast on Jan 6, 2026. Earnings updates showed substantial R&D investment and cash intended to fund operations into 2027, while frequent conference participation maintained investor engagement ahead of these pivotal readouts.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-07-03

The company has an active Form S-3 shelf registration dated Jul 3, 2025, currently marked as not effective and with no recorded usage, which could provide future financing flexibility once effective.

Market Pulse Summary

The stock moved -7.2% in the session following this news. A negative reaction despite this scheduling announcement could fit a pattern where the market de-risks ahead of pivotal readouts. Prior Alumis events, including earnings and trial milestones, tended to generate relatively small moves, so a sharp decline would stand out. Concerns could have centered on binary outcome risk for the Phase 3 ONWARD data and the company’s ability to fund future development, even with an existing but unused S-3 shelf registration in place.

Key Terms

phase 3 medical

"topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

plaque psoriasis medical

"envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday"

A chronic autoimmune skin condition that causes raised, red, scaly patches where the skin sheds too quickly, like a tree producing bark in clumps instead of renewing smoothly. It matters to investors because prevalence, severity, and treatment options drive demand for therapies, shape clinical trial design and regulatory review, and affect potential market size, pricing and reimbursement for drugs or devices aimed at relieving symptoms or altering the underlying immune response.

AI-generated analysis. Not financial advice.

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET –

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Conference Call and Webcast Details
Alumis’ conference call and webcast to discuss the topline data results from the Phase 3 ONWARD clinical program will begin Tuesday, January 6, 2026, at 8:00 a.m. ET. To access the live webcast please access this link or visit the “Events” page of the “Investors" section of the Alumis website at www.alumis.com. A replay of the webcast will be made available on the Company’s website following the call.

About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.

Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding the anticipated timing and availability of clinical data from the ONWARD Phase 3 clinical program. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com

FAQ

When will Alumis (ALMS) report Phase 3 ONWARD topline data for envudeucitinib?

Alumis will report topline Phase 3 ONWARD data on January 6, 2026.

What time is the Alumis (ALMS) conference call and webcast to discuss ONWARD results?

The conference call and webcast will begin at 8:00 a.m. ET on January 6, 2026.

How can investors access the Alumis (ALMS) live webcast for the ONWARD topline results?

Access the live webcast via the company website under Investors > Events or the webcast link on www.alumis.com.

Will Alumis (ALMS) make a replay of the ONWARD webcast available?

Yes. A replay of the webcast will be made available on Alumis’ website following the call.

What clinical program is Alumis (ALMS) reporting on January 6, 2026?

Alumis is reporting topline data from the Phase 3 ONWARD clinical program for envudeucitinib in moderate-to-severe plaque psoriasis.

Which patient population is covered by the ONWARD Phase 3 results Alumis (ALMS) will report?

The ONWARD Phase 3 topline results cover patients with moderate-to-severe plaque psoriasis.